<DOC>
	<DOCNO>NCT02194166</DOCNO>
	<brief_summary>This multicenter study patient HER2-positive eBC investigate patient ' pain discomfort subcutaneous ( SC ) trastuzumab ( Herceptin ) administer either via single-use injection device ( SID ) via vial manual administration use hand-held syringe ( SC vial ) . In total , patient wil obtain least 18 cycles/1 year trastuzumab ( 4 cycle IV 14 cycle SC trastuzumab ) .</brief_summary>
	<brief_title>An Open-Label Randomized Study Investigate Tolerability Subcutaneous ( SC ) Trastuzumab Administration Patients With HER2-Positive Early Breast Cancer ( eBC ) Using Either Single-Use Injection Device Manual Administration</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female male patient age &gt; /= 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Hormonal therapy allow per institutional guideline Left ventricular ejection fraction ( LVEF ) &gt; /= 55 % measure echocardiography ( ECHO ) prior first dose trastuzumab HER2positive disease immunohistochemistry ( IHC ) 3+ insitu hybridization ( ISH ) positive determine local laboratory experienced/certified HER2expression test use accurate validate assay Histologically confirm nonmetastatic primary invasive adenocarcinoma breast No evidence residual , locally recurrent metastatic disease completion surgery chemotherapy , concurrent chemotherapy ( neoadjuvant adjuvant ) Patients complete ( neo ) adjuvant treatment patient adjuvant chemotherapy doxorubicin cyclophosphamide ( AC ) 4 subsequent cycle Herceptin combination paclitaxel docetaxel indicate per local practice Not 3 month elapse since last dose adjuvant chemotherapy case subsequent treatment scheme Previous neoadjuvant adjuvant breast cancer treatment approve investigational antiHER2 agent History malignancy affect compliance protocol interpretation result . Patients curatively treat carcinoma situ cervix basal cell carcinoma , patient curatively treated malignancy diseasefree least 5 year , eligible . Patients previous ductal carcinoma situ ( DCIS ) breast also eligible study Patients severe dyspnea rest require supplementary oxygen therapy Patients concurrent serious disease may interfere plan treatment , include severe pulmonary conditions/illness Prior maximum cumulative dose doxorubicin &gt; 360 mg/m2 maximum cumulative dose epirubicin &gt; 720 mg/m2 equivalent Serious cardiac illness medical condition would preclude use trastuzumab , specifically : history document congestive heart failure ( CHF ) , highrisk uncontrolled arrhythmia , angina pectoris require medication , clinically significant valvular disease , evidence transmural infarction electrocardiogram ( ECG ) , diagnose poorly control hypertension Known infection human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Pregnant lactate woman Concurrent enrollment another clinical trial use investigational anticancer treatment , include hormonal therapy , bisphosphonate therapy immunotherapy , within 28 day prior first dose study treatment Known hypersensitivity trastuzumab , murine protein , excipients HerceptinÂ® , adhesive SC device , history severe allergic immunological reaction , e.g . difficult control asthma Inadequate bone marrow , hepatic , renal function Major surgical procedure significant traumatic injury within 14 day prior first dose study treatment anticipate need major surgery course study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>